The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features

REFERENCES

• Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of Tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351, 2817–2826.
   PubMed Web of Science ®Google Scholar
• Cronin, M.; Pho, M.; Dutta, D.; Stephans, J.C.; Shak, S.; Kiefer, M.C.; Esteban, J.M.; Baker, J.B. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164, 35–42.
   PubMed Web of Science ®Google Scholar
• Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; Costantino, J.P.; Geyer, C.E.; Wickerham, D.L.; Wolmark, N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24, 3726–3734.
   PubMed Web of Science ®Google Scholar
• Albain, K.S.; Barlow, W.E.; Shak, S.; Hortobagyi, G.N.; Livingston, R.B.; Yeh, I.T.; Ravdin, P.; Bugarini, R.; Baehner, F.L.; Davidson, N.E.; Sledge, G.W.; Winer, E.P.; Hudis, C.; Ingle, J.N.; Perez, E.A.; Pritchard, K.I.; Shepherd, L.; Gralow, J.R., Yoshizawa, C.; Allred, D.C.; Osborne, C.K.; Hayes, D.F.; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010, 11, 55–65.
   PubMed Web of Science ®Google Scholar
• Mamounas, E.P.; Tang, G.; Fisher, B.; Paik, S.; Shak, S.; Costantino, J.P.; Watson, D.; Geyer, C.E.; Wickerham, D.L.; Wolmark, N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28, 1677–1683.
   PubMed Web of Science ®Google Scholar
• Asad, J.; Jacobson, A.F.; Estabrook, A.; Smith, S.R.; Boolbol, S.K.; Feldman, S.M.; Osborne, M.P. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surgery 2008, 196, 527–529.
   PubMed Web of Science ®Google Scholar
• Lo, S.S.; Mumby, P.B.; Norton, J.; Rychlik, K.; Smerage, J.; Kash, J.; Chew, H.K.; Gaynor, E.R.; Hayes, D.F.; Epstein, A.; Albain, K.S. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010, 28, 1671–1676.
   PubMed Web of Science ®Google Scholar
• Weidner, N.; Moore, D.H.; Vartanian, R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. Hum Pathol 1994, 25, 337–342.
   PubMed Web of Science ®Google Scholar
• Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19, 403–410.
   PubMed Web of Science ®Google Scholar
• Allred, D.C.; Harvey, J.M.; Berardo, M.; Clark, G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11, 155–168.
   PubMed Web of Science ®Google Scholar
• Mohsin, S.K.; Weiss, H.; Havighurst, T.; Clark, G.M.; Berardo, M.; LeRoanh, D.; To, T.V.; Qian, Z.; Cove, R.R.; Allred, D.C. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004, 17, 1545–1554.
   PubMed Web of Science ®Google Scholar
• Wolff, A.C.; Hammond, E.M.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; McShane, L.M.; Paik, S.; Pegram, M.D.; Perez, E.A.; Press, M.F.; Rhodes, A.; Sturgeon, C.; Taube, S.E.; Tubbs, R.; Vance, G.H.; van de Vijver, M.; Wheeler, T.M.; Hayes, D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131, 18–43.
   PubMed Web of Science ®Google Scholar
• Zujewski, J.A.; Kamin, L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008, 4, 603–610.
   PubMed Web of Science ®Google Scholar
• Ademuyiwa, F.O.; Thorat, M.A.; Jain, R.K.; Nakshatri, H.; Badve, S. Expression of forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol 2010, 23, 270–275.
   PubMed Web of Science ®Google Scholar
• Wolf, I.; Ben-Baruch, N.; Shapira-Frommer, R.; Rizel, S.; Goldberg, H.; Yaal-Hahoshen, N.; Klein, B.; Geffen, D.B.; Kaufman, B. Association between standard clinical and pathologic characteristics and the 21-gene Recurrence Score in breast cancer patients. Cancer 2008, 112, 731–736.
   PubMed Web of Science ®Google Scholar
• Gwin, K.; Pinto, M.; Tavassoli, F.A. Complementary value of the Ki-67 proliferation index to the Oncotype DX Recurrence Score. Int J Surg Pathol 2009, 17, 303–310.
   PubMed Web of Science ®Google Scholar
• Flanagan, M.B.; Dabbs, D.J.; Brufsky, A.M.; Beriwal, S.; Bhargava, R. Histopathologic variables predict OncotypeDX Recurrence Score. Mod Pathol 2008, 21, 1255–1261.
   PubMed Web of Science ®Google Scholar
• Geradts, J. Molecular prediction of recurrence of breast cancer. N Engl J Med 2005, 352, 1605–1606.
   PubMedGoogle Scholar
• Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17, 1474–1481.
   PubMed Web of Science ®Google Scholar